Match!

Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non‐surgical and bariatric surgery patients

Published on Jun 1, 2019in Diabetes, Obesity and Metabolism6.133
· DOI :10.1111/dom.13672
Mohamed Suliman3
Estimated H-index: 3
(Imperial College London),
Adam Buckley5
Estimated H-index: 5
(Imperial College London)
+ 4 AuthorsMaha T Barakat5
Estimated H-index: 5
(Imperial College London)
Abstract
  • References (15)
  • Citations (4)
📖 Papers frequently viewed together
10 Citations
15 Citations
8 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References15
Newest
#1Ye Liu (PKU: Peking University)H-Index: 8
#2Qing Tian (PKU: Peking University)H-Index: 5
Last. Tianpei Hong (PKU: Peking University)H-Index: 14
view all 5 authors...
3 CitationsSource
#1John Wilding (University of Liverpool)H-Index: 58
In the UK, over one-quarter of the adult population have obesity (body mass index ≥30 kg m-2 ). This has major implications for patients' health and the National Health Service. Despite published studies showing that significant weight loss can be achieved and maintained in primary care, and guidance from the National Institute for Health and Care Excellence, weight management services are inconsistently implemented. This may be due primarily to workload and financial constraints. There is also ...
3 CitationsSource
#1Ashkan Afshin (UW: University of Washington)H-Index: 33
#2Mohammad H. Forouzanfar (UW: University of Washington)H-Index: 54
Last. Christopher MargonoH-Index: 162
view all 153 authors...
BACKGROUND Although the rising pandemic of obesity has received major attention in many countries, the effects of this attention on trends and the disease burden of obesity remain uncertain. METHOD ...
934 CitationsSource
#1C. W. le Roux (Imperial College London)H-Index: 52
#2A. Astrup (UCPH: University of Copenhagen)H-Index: 96
Last. James Alan Simon (University of Liège)H-Index: 1
view all 200 authors...
Summary Background Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. Methods In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m 2 , or...
120 CitationsSource
#1Fatima Cody Stanford (Harvard University)H-Index: 12
#2Nasreen Alfaris (Harvard University)H-Index: 6
Last. Louis J. Aronne (Columbia University)H-Index: 40
view all 10 authors...
Abstract Background Patients who undergo bariatric surgery often have inadequate weight loss or weight regain. Objectives We sought to discern the utility of weight loss pharmacotherapy as an adjunct to bariatric surgery in patients with inadequate weight loss or weight regain. Setting Two academic medical centers. Methods We completed a retrospective study to identify patients who had undergone bariatric surgery in the form of a Roux-en-Y gastric bypass (RYGB) or a sleeve gastrectomy from 2000–...
34 CitationsSource
#1Ken Fujioka (Scripps Health)H-Index: 31
#2Patrick M. O'Neil (MUSC: Medical University of South Carolina)H-Index: 34
Last. John Wilding (University of Liverpool)H-Index: 58
view all 9 authors...
Objective To identify an early response criterion for predicting ≥5% weight loss with liraglutide 3.0 mg at week 56 and to compare efficacy outcomes in early responders (ERs) and early nonresponders (ENRs). Methods Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks. Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weigh...
22 CitationsSource
#1Rohan Khera (Roy J. and Lucille A. Carver College of Medicine)H-Index: 16
#2M. Hassan Murad (Mayo Clinic)H-Index: 94
Last. Siddharth Singh (UCSD: University of California, San Diego)H-Index: 39
view all 9 authors...
Importance Five medications have been approved for the management of obesity, but data on comparative effectiveness are limited. Objective To compare weight loss and adverse events among drug treatments for obesity using a systematic review and network meta-analysis. Data Sources MEDLINE, EMBASE, Web of Science, Scopus, and Cochrane Central from inception to March 23, 2016; clinical trial registries. Study Selection Randomized clinical trials conducted among overweight and obese adults treated w...
155 CitationsSource
#1A. Blackman (U of T: University of Toronto)H-Index: 2
#2Gary D. Foster (TU: Temple University)H-Index: 62
Last. Emmanuel Mignot (Stanford University)H-Index: 91
view all 9 authors...
Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
65 CitationsSource
#1Melanie J. Davies (University of Leicester)H-Index: 82
Last. Ralph A. DeFronzoH-Index: 139
view all 9 authors...
Importance Weight loss of 5% to 10% can improve type 2 diabetes and related comorbidities. Few safe, effective weight-management drugs are currently available. Objective To investigate efficacy and safety of liraglutide vs placebo for weight management in adults with overweight or obesity and type 2 diabetes. Design, Setting, and Participants Fifty-six–week randomized (2:1:1), double-blind, placebo-controlled, parallel-group trial with 12-week observational off-drug follow-up period. The study w...
240 CitationsSource
#1Xavier Pi-SunyerH-Index: 20
#2A. AstrupH-Index: 96
Last. John WildingH-Index: 58
view all 11 authors...
BACKGROUND Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagonlike peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by ...
467 CitationsSource
Cited By4
Newest
#1Romano SchneiderH-Index: 2
#2Marko KraljevićH-Index: 9
Last. Tarik DelkoH-Index: 5
view all 7 authors...
The evidence is strong that bariatric surgery is superior to medical treatment in terms of weight loss and comorbidities in patients with severe obesity. However, a considerable part of patients presents with unsatisfactory response in the long term. It remains unclear whether postoperative administration of glucagon-like peptide-1 analogues can promote additional benefits. Therefore, a systematic review of the current literature on the management of postoperative GLP-1 analogue usage after meta...
Source
#1Nawfal W. Istfan (BMC: Boston Medical Center)H-Index: 14
#2Wendy A. Anderson (BMC: Boston Medical Center)H-Index: 9
Last. Caroline M. Apovian (BMC: Boston Medical Center)H-Index: 48
view all 6 authors...
OBJECTIVE: Weight regain (WR) after Roux-en-Y gastric bypass surgery (RYGB) starts to occur 2 years after surgery, ultimately affecting at least 25% of patients. A limited number of studies have evaluated the impact of antiobesity medications (AOMs) on this phenomenon. METHODS: This study reviewed the electronic medical records of 1,196 patients who underwent RYGB between 2004 and 2015. WR was evaluated by comparing each patient's weight during subsequent postoperative office visits to nadir wei...
1 CitationsSource
#1Phong Ching Lee (SGH: Singapore General Hospital)H-Index: 4
#2John DixonH-Index: 79
Last. Chin Hong Lim (SGH: Singapore General Hospital)H-Index: 3
view all 4 authors...
PURPOSE OF REVIEW: This review aims to evaluate the latest evidence on the treatment options for perceived poor responders to bariatric surgery and provide practitioners with a guide on when to consider revisional surgery and when to consider alternatives. RECENT FINDINGS: The use of adjuvant pharmacotherapy has been increasingly described in the literature as an adjunct to primary bariatric surgery, in order to attain more weight loss or better control of obesity-related complications. The newe...
Source
Abstract Setting Tertiary Hospital Objectives Insufficient weight loss or secondary weight regain with or without recurrence of comorbidity can occur years after laparoscopic Roux-en-Y gastric bypass (LRYGB). In selected patients, increasing restriction or adding malabsorption may be a surgical option after conservative measures failed. Methods Retrospective analysis of prospectively collected data from a cohort of 1150 LRYGB patients. Included were patients, who underwent revisional bariatric s...
Source
#1Sean Wharton (UPenn: University of Pennsylvania)H-Index: 6
#2Christiane L. Haase (Novo Nordisk)H-Index: 4
Last. Rebecca A. G. Christensen (UPenn: University of Pennsylvania)H-Index: 1
view all 9 authors...
Source
#1Sean Wharton (UPenn: University of Pennsylvania)H-Index: 6
#2Christiane L. Haase (Novo Nordisk)H-Index: 4
Last. Rebecca A. G. Christensen (UPenn: University of Pennsylvania)H-Index: 1
view all 9 authors...
1 CitationsSource
#1Chen Hsiu Lin (TMU: Taipei Medical University)
#2Li Shao (Tongji University)H-Index: 1
Last. Zhongmin Liu (Tongji University)H-Index: 26
view all 8 authors...
ABSTRACTIntroduction: The prevalence of obesity is increasing worldwide and associated conditions, particularly type 2 diabetes mellitus (T2DM), also show increasing prevalence. Lifestyle intervent...
Source
#1Sangeeta R. Kashyap (Cleveland Clinic)H-Index: 29
#2Karim G. Kheniser (Cleveland Clinic)H-Index: 2
Last. Bartolome Burguera (Cleveland Clinic)H-Index: 20
view all 6 authors...
Setting Bariatric surgery is indicated for patients diagnosed with obesity and type 2 diabetes. Many patients achieve type 2 diabetes remission soon after bariatric surgery. Even though most maintain good glycemic control, remission is not maintained in all patients, and as a result, some patients may relapse. Type 2 diabetes relapse is common in patients who regain weight; weight regain is prevalent 1 to 2 years after surgery. Additional pharmacotherapy may be required to aid bariatric surgery ...
Source
#1Sean Wharton (UPenn: University of Pennsylvania)H-Index: 6
#2Aiden Liu (Novo Nordisk)H-Index: 1
Last. Rebecca A. G. Christensen (UPenn: University of Pennsylvania)H-Index: 1
view all 9 authors...
Source
#1Alexis Sudlow (Southmead Hospital)H-Index: 1
#2C. W. le Roux (UCD: University College Dublin)H-Index: 52
Last. Dimitri J. Pournaras (Southmead Hospital)
view all 3 authors...
There is a growing need for treatments for patients who would benefit from further weight loss following bariatric surgery or weight loss maintenance/long-term disease remission. Currently, therapeutic options are limited. Although largely dismissed previously, advances in weight loss pharmacotherapy now offer the possibility of achieving clinically significant weight loss. Historical comparisons drawn between the effects of medications vs surgery are generally inaccurate as novel classes of ant...
Source